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Abstract: Background: Movement Disorders Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
and Unified Dyskinesia Rating Scale (UDysRS) were developed as standard tools to rate Parkinson’s disease
(PD) and drug-induced dyskinesias of PD. As these scales have become widely used, there is a need for
translation to non-English languages. Here we present the standardization for the Turkish translations.
Methods: The scales were translated into Turkish and then back-translated to English. These back-
translations were reviewed by the MDS team. After cognitive pretesting, movement disorder specialists from
nine centers tested 352 patients for MDS-UPDRS, and 250 patients for UDysRS. Confirmatory factor analyses
(CFAs) were used to determine if the factor structures for the reference standards could be confirmed in the
Turkish data. The comparative fit indexes (CFIs) for the scales were required to be 0.90 or higher. Exploratory
factor analyses (EFAs) were conducted to explore the underlying factor structure without the constraint of a
pre-specified factor structure.
Results: For both scales, the CFIs were 0.94 or greater as compared to the reference standard factor
structures. The factor structures were consistent with that of reference standards, although there were some
differences in some areas as compared to the EFA of the reference standard dataset. This may be due to the
inclusion of patients with different stages of PD and different cultural properties of raters and patients.
Conclusions: These results demonstrate that the Turkish translations of MDS-UPDRS and UDysRS have
adequate clinimetric properties. They are established as the official translations and can be reliably used in
Turkish speaking populations.
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CLINICAL PRACTICE
Measurement is a sine qua non of science.1 The most frequently
used way to measure clinical parameters, such as symptoms or
signs of a disease, is rating scales. A rating scale should bereli-
able (a given clinical parameter gets the same score by every
rater at every time point in time) and valid (measures what it
intends to measure). Demonstration that a rating scale is reli-
able and valid, requires clinical testing supported by appropriate
statistics. This has been done by the International Parkinson
and Movement Disorders Society (MDS), for the Movement
Disorders Society-sponsored Unified Parkinson’s Disease Rat-
ing Scale (MDS-UPDRS) and Unified Dyskinesia Rating Scale
(UDysRS).
The UPDRS has often been the main outcome measure
in clinical trials in Parkinson’s disease (PD).2 The scale con-
sisted of four different parts based on mentation, behavior,
and mood; daily life activities, motor examination, and treat-
ment complications. It was originally designed to become a
single scale used by the clinicians all around the world so
that comparisons between different studies could be made
reliably.3 Although it fulfilled this original aim, the scale had
limitations due to ambiguous wording, weakness in assessing
various non-motor symptoms, lack of uniform instructions,
and several metric flaws.4,5 Thus, the MDS-UPDRS was
designed to be more comprehensive than the original
UPDRS, with new items devoted to several non-motor
symptoms of PD. It also provides more detailed instructions
and includes both patients and caregivers for the assessment
of various motor and non-motor aspects of daily living.6 The
five-point scoring system for each item was retained, and
clinical anchors of normal (0), slight (1), mild (2), moderate
(3), and severe (4) were added to provide a consistency
across ratings.
The UDysRS was developed as a comprehensive tool to rate
all aspects of drug-induced dyskinesias in PD.7 It has four parts:
(1) historical disability (patient perceptions) of on-dyskinesia
impact; (2) historical disability (patient perceptions) of off-dysto-
nia impact; (3) objective ımpairment (dyskinesia severity,
anatomical distribution, and type [choreic or dystonic] based on
four activities observed or video-recorded); (4) objective disabil-
ity based on part three activities.
Simple translation of a validated rating scale into another
language does not necessarily mean that the scale would also
be valid and reliable in the translated language. For instance,
the word “trick” has associations with “wittiness” in English,
whereas it could mean “dishonesty” in Turkish; hence, a
direct translation of “sensory trick” would make a cervical
dystonia scale’s sensory trick item useless. Consequently,
translation of a clinical scale, similar to its development,
requires an equally rigorous clinical validation and advanced
statistics.
The method for the validation of the scales have been previ-
ously determined by the original team involved in the develop-
ment and translation processes of these scales.8 The purpose of
this approach is to assure that the interpretation of the scales are
consistent acrossall languages.Here we present the Turkish
validation studies of MDS-UPDRS and UDysRSbased on this
predetermined method.
Methods
Translation
The scales were translated into Turkish by a team of Turkish
investigators who were fluent in English and led by one of the
authors (MCA). These translations were then back-translated
into English by a team not involved in the original translation,
but acquainted with the use of both scales. These back-transla-
tions were reviewed by an US team (Stebbins, Goetz, LaPelle,
Tilley).
Cognitive Pretesting
Cognitive pretesting is a qualitative approach assessing tool
usability (or ease of completion) in terms of task difficulty for
examiner and respondent as well as respondent interest, atten-
tion span, discomfort and comprehension.9 All items in the
MDS-UPDRS were subjected to pretesting. Questions
included in cognitive pretesting were: Instructions to Raters
and Instructions to Patients, Time Spent with Dyskinesia,
Time with OFF Dystonia, Chewing and Swallowing, Hobbies,
Walking and Balance, Exciting or Emotional Settings, Objec-
tive Impairment Ratings, and Objective Disability Ratings.
Based on the initial cognitive pretesting results, translation,
back-translation, and cognitive pretesting phases were repeated
for items in need of improvement. Over all, five movement
disorder specialists, 25 patients for MDS-UPDRS, and 13 for
UDysRS were involved in this process. Selected items were
reassessed based on the initial results. As no problems were
noted after the cognitive pretesting, the final translation was
obtained.
Testing of the Turkish Version
A team of experienced Turkish movement disorder specialists
from nine centers, including Ankara University, Cumhuriyet
University, Ege University, Eskisehir Osmangazi University,
Gazi University, Hacettepe University, Istanbul University,
Mersin University, and Uludag University took part in the test-
ing phase. All raters were trained on the MDS-UPDRS and
UDysRS through the MDS Certificate Program.10,11 Ethics
approval was obtained from the local ethics committee. Only
participants providing informed consents were included. The
sample size requirements for each scale were based on the num-
ber of items and scaling characteristics, thus a minimum of 350
patients were required for the MDS-UPDRS validation and a
minimum of 250 paients were required for the UDysRS valida-
tion.12 Patients with missing values within a part in the MDS-
UPDRS or the UDysRS were excluded from the analysis of
that specific part. Patient data for both scales were anonymously
transferred to a secure website.
MOVEMENT DISORDERS CLINICAL PRACTICE 2018; 5(1): 54–59. doi: 10.1002/mdc3.12556 55
M.C. AKBOSTANCI ET AL. RESEARCH ARTICLE
Data Analysis
MDS-UPDRS M-plus, Version 7 and UDysRS M-plus, Ver-
sion 6.11 were used to perform confirmatory and secondary
exploratory factor analyses. An unweighted least squares (ULS)
approach to factor estimation was used, minimizing the sum of
squared differences between observed and estimated correlation
matrices not counting diagonal elements. An orthogonal CF-
VARIMAX rotation setting the factors to be uncorrelated was
used to assist in interpretation of the factors.
In the UDysRS, Question 1 (time of ON dyskinesia) and
Question 12 (time of OFF dystonia) were considered as
descriptive indices, rather than impairment or disability mea-
sures, and were omitted from the factor analysis. In order to
maximize the accuracy of these time indices, three clarifying
statements were added to reconcile time-based questions with
the patient/caregiver questionnaire and interview items. In the
initial instructions, the rater was informed to review the patient
questionnaire after it was filled-out. This was done to make sure
that when individual-item scores pointed to the presence of
dyskinesia or dystonia (over the previous week), the time-based
items supported this ascertion (rating 1, 2, 3, or 4, but not
zero). The same alerting question was presented at the end of
each questionnaire section (ON dyskinesia and OFF dystonia).
Primary Analysis
A confirmatory factor analysis (CFA) was conducted to deter-
mine if the factor structure for the Turkish scales could be con-
firmed against the reference standard versions (English language
MDS-UPDRS and Spanish version of the UDysRS).6,13 The
CFA was conducted for the total score of the UDysRS and for
the total score from each of the four parts of the MDS-UPDRS
(Parts I to IV) with the Turkish data constrained to fall into the
factors defined by the reference standard. The CFA results were
evaluated based on the comparative fit ındex (CFI). To establish
a successful translation of the scales, and to designate these as
OFFICIAL MDS translations, the CFI for each part (I-IV) of
the translated MDS-UPDRS and UDysRS was required to be
0.90 or higher relative to the reference standard versions. Mean
and variance adjusted weighted least square (WLSMV) estimator
was used to confirm model fit. For both the MDS-UPDRS
and UDysRS, goodness of fit was determined by root mean
square error of approximation (RMSEA). This is a population-
based index relying on the noncentral v2 distribution, which is
the distribution of the fitting function when the fit of the
model is not perfect.
Secondary Analysis
As secondary analysis an exploratory factor analysis (EFA) of the
Turkish version of the scales was conducted to explore the
underlying factor structure without the constraint of a pre-spe-
cified factor structure. An unweighted least squares (ULS)
approach was used. To determine the factor number to be
retain in each MDS-UPDRS Part and UDysRS, a subjective
SCREE test, alongside the information from the SCREE plot
of the reference standard versions, was used. The subjective
SCREE test uses a scatter plot of eigenvalues, plotted against
their ranks with respect to magnitude, to extract as many factors
as there are eigenvalues that fall before the last large drop (i.e.,
an “elbow” shape) in the plot.14 Once the factors were chosen,
an item was retained in a given factor if the factor loading for
that item was 0.40 or greater. To assist interpretation of the fac-
tors, an orthogonal CF-VARIMAX rotation was used which
sets the factors to be uncorrelated.
Results
The demographic characteristics of the patient population are
shown in Table 1 and Fig. 1. The study population included
native Turkish-speaking PD patients with or without dyskinesia.
Cognitive Pretesting
MDS-UPDRS
Five raters used structured interview to evaluate a total of 15
PD patients for cognitive pretesting. On the first round of
cognitive pretesting, minor changes were suggested for the
instructions and selected wording for individual items. As most
hobbies among Turkish people are gender-specific, it was diffi-
cult to find a hobby which could be shown as an example that
would be valid for both sexes; eventually “following a series on
television” was chosen. Following these modifications, a second
round of cognitive pretesting was performed with an indepen-
dent sample of 10 PD patients and 3 raters. No items were
identified as problematic during this second round. The modi-
fied version of the scale was approved as the official working
document of the Turkish MDS-UPDRS for testing in a larger
group of PD patients.
UDysRS
The UDysRS was performed the same way as the MDS-
UPDRS; the first round with 10 patients and three raters. After
some minor changes in wording, the second round was com-
pleted with three patients and two raters with no additional
issues. The modified version of the scale was approved as the
official working document of the Turkish UDysRS.
Primary Analysis: Confirmatory
Factor Analyses (CFA)
For all four parts of the Turkish MDS-UPDRS, the CFI, in
comparison with the reference standard factor structure, was
0.94 or greater (Table 2). For UDysRS, the CFI, in comparison
with the reference standard factor structure, was 0.98. Our pre-
specified criterion was a CFI of 0.90 or greater. Hence, the
pre-specified reference standard factor structure was confirmed
in the Turkish dataset.
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Secondary Analysis: Exploratory
Factor Analyses (EFA)
Mds-updrs
Similar numbers of factors were extracted for all four parts of
MDS-UPDRS from the Turkish and reference standard
versions.
Our EFA analysis for the Turkish dataset differed from the
EFA of the reference standard dataset in some areas. For Part
I, in contrast to the English version of the MDS-UPDRS,
“fatigue” loaded on factor 2. “Sleep problems, daytime
sleepiness, and pain and other sensations” did not load on
any of the two factors. For Part II, “speech” and “eating
tasks” loaded on more than one factor with factor loading
≥ 0.40. In Part III, “rigidity” items loaded on factor 3, 4,
and 5. “Toe tapping” and “leg agility” items loaded on fac-
tor 1, 4, and 5. In Part IV, “painful off state dystonia”
loaded on both factors.
UDysRS
From the SCREE Plot we extracted three factors. The factor
structure of Turkish UDysRS was consistent with that of refer-
ence standard UDysRS, differing from the EFA of the reference
standard dataset only in few areas. Most of the items that loaded
on different factors in the two versions also had cross loadings
on multiple factors.
Discussion
The objective of this study was to develop a validated Turkish
translation of the MDS-UPDRS and UDysRS, equivalent to
the original version.
The original English version of these scales included clear
instructions to ensure all patients could understand the questions
easily. We emphasized the need for this clarity during the trans-
lation process. Since both rating scales had CFI’s that were
higher than the pre-specified 0.90 in comparison with the
TABLE 1 The demographic characteristics of the patients
Total Male, n (%) Age Duration of
dyskinesia
(years)
Dyskinesia
severity
range
Duration of
Parkinson’s
disease (years)
Turkish 250 136 (54.4) 63.5 (10.4) 3.8 (3.6) 0-82 11.0 (5.9)
Reference
Standard
(Spanish)
253 122 (48.2) 69.2 (10.5) 4.9 (4.6) 12.5 (6.8)
Turkish 352 201 (57.1) 63.4 (10.6) na na 9.5 (6.2)
Reference
Standard
(English)
876 554 (63.2) 67.5 (10.9) na na 8.3 (6.7)
All variables are reported as mean (standard deviation) unless stated otherwise. na=not available.
FIG. 1. The percentage of patients recruited for MDS-UPDRS/UDysRS (the overall distribution of population) from each region in Turkey.
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reference standard language factor structure, our translated scales
appear to be measuring similar constructs as the original ver-
sions. Thus, both of the scales were accepted as official MDS
Turkish translations (Table 2).
As several different centers contributed to this study, we
were able to collect data from all of the regions in Turkey.
Although the distribution of our patients was not the same as
overall population distribution, we believe our results still
provide an adequate geographical representation of the coun-
try as a number of patients from all of the geographical
regions were included (Fig. 1).15 Therefore, these scales can
be reliably used in Turkish-speaking populations living in
Turkey, Cyprus, and European countries. However, they
cannot be used in Turkish-speaking populations living in
Azerbaijan, Turkmenistan, Uzbekistan, Kazakhstan, Syria, and
Iraq as there are substantial differences in the dialects. Origi-
nal Turkish texts can be found at the International Parkinson
and Movement Disorders Society’s web page (http://www.
movementdisorders.org/MDS/Education/Rating-Scales.htm),
and can be used for research or clinical care programs with
the society’s permission.
The purpose of EFA is to examine subtle differences in the fac-
tor loadings that may be observed across various languages and cul-
tures.Similar to other translations of the rating scales, the Turkish
dataset differed from the reference standard language datasets in
some areas9 The variation may stem from different cultural back-
grounds of raters and patients. Perceptions of some symptoms may
show transcultural variability. For example, in the Japanese valida-
tion of MDS-UPDRS, a much greater percentage (62.2%) of
patients had zero scores for cognitive impairment when compared
to the English-speaking sample (48.9%).16 Another source of vari-
ability may be inclusion of patients with different stages of PD.
Since we conducted validation studies of both MDS-UPDRS and
UDysRS simultaneously, our first 250 patients were selected to
have dyskinesias by design. This may be a cause of variability speci-
fic to Turkish dataset.
Unlike the MDS-UPDRS, the UDysRS was not validated
in a large population in the original English version. The first
large-scale field testing was done with the Spanish version.
Thus, reliability and construct validity testing were done by
comparing Spanish and Turkish versions.8,13 To become an
official translation, the scale has to undergo a confirmatory
factor analysis against the Spanish-version factor structure.
Similar to MDS-UPDRS, a CFI over 0.90 (0.98) was
obtained for Turkish UDysRS, establishing the scale as an
official translation.
All published translations reported CFI’s greater than 0.90,
which indicates a strong consistency with the reference standard
languages. On the other hand, all showed some variability in
EFAs in the secondary analyses, these were accepted to be
within a reasonable range by the analysis team.
As Lord Nelson said, “One’s knowledge of science begins when he
can measure what he is speaking about and express it in numbers.”17
The most trustworthy way of quantizing abundant aspects of
neurological diseases are rating scales that are proven to be reli-
able and valid. With an invaluable effort of an MDS-assigned
team, it is now possible to rate PD in several languages, includ-
ing Turkish, more reliably than ever.
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